Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US17550173Application Date: 2021-12-14
-
Publication No.: US11713311B2Publication Date: 2023-08-01
- Inventor: Eiji Kimura , Masaki Ogino , Yasuhisa Kohara , Tomoko Ohashi , Tomohiro Kaku , Yuya Oguro , Shigemitsu Matsumoto , Takeshi Wakabayashi , Norihito Tokunaga , Taku Kamei , Mitsuhiro Ito
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
- Priority: JP 17146744 2017.07.28
- Main IPC: C07D409/12
- IPC: C07D409/12 ; C07D401/12 ; A61P25/28 ; A61P25/24 ; A61P25/06 ; A61K9/20 ; A61K9/48 ; C07D231/56 ; C07D235/06 ; C07D249/18

Abstract:
Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I):
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
Public/Granted literature
- US20220388995A1 HETEROCYCLIC COMPOUND Public/Granted day:2022-12-08
Information query